Hologic stock hits 52-week low at $61.67 amid market shifts

In a challenging market environment, Hologic Inc . (NASDAQ:HOLX) stock has touched a 52-week low, dipping to $61.67. The medical technology company, known for its diagnostic products and surgical solutions, has faced a significant downturn over the past year, with its stock price reflecting a 1-year change of -18.71%. Despite the decline, InvestingPro analysis indicates the stock is currently undervalued, with a P/E ratio of 19.8x and strong free cash flow yield of 8%. Investors are closely monitoring the company’s performance as it navigates through the headwinds that have led to this notable decline from its previous highs. The current price level presents a critical juncture for Hologic, as market participants consider the stock’s potential for recovery or further descent in the coming months. Analyst targets range from $70 to $95, suggesting potential upside, while InvestingPro subscribers can access 8 additional key insights about HOLX’s financial health and growth prospects through the comprehensive Pro Research Report.

In other recent news, Hologic Inc. reported its financial results for the first quarter of fiscal year 2025, with earnings per share (EPS) of $1.03, slightly surpassing the forecast of $1.01. However, the company fell short on revenue expectations, reporting $1.022 billion against a projected $1.03 billion. Following the earnings announcement, Mizuho (NYSE:MFG) Securities lowered its price target for Hologic from $87 to $83, maintaining an Outperform rating. The adjustment was influenced by Hologic’s lowered second-quarter and full-year 2025 forecasts, which did not meet analyst predictions due to factors like a strong US dollar and anticipated reductions in Breast Health capital sales.

Additionally, Hologic received FDA 510(k) clearance for its Aptima SARS-CoV-2 assay, a significant regulatory milestone that underscores the test’s utility in managing COVID-19. In terms of analyst ratings, Needham reiterated a Hold rating on Hologic’s stock, noting the company’s mixed financial results and challenges in its Breast Health segment. Despite these challenges, Hologic maintained its EPS guidance for fiscal year 2025, while adjusting its revenue forecast downward by $100 million.

In corporate news, Hologic announced an executive transition, with John Griffin, the General Counsel, set to retire and become a Special Advisor to the Chairman, President, and CEO, effective May 1, 2025. Anne Liddy, currently Vice President and Assistant General Counsel, will assume the General Counsel position. These developments reflect Hologic’s ongoing adjustments and strategic planning amid current market conditions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.